{"id":"W2936127489","doi":"10.1016/s2352-3018(19)30053-0","title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":105,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institutes of Health; Gilead Sciences; Merck; National Institute of Allergy and Infectious Diseases; Delaney AIDS Research Enterprise; Henry M. Jackson Foundation","keywords":"Medicine; Placebo; Human immunodeficiency virus (HIV); Antibody; Double blind; Internal medicine; Immunology; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001672773,0.001906577,0.003530269,0.0003675081,0.0005006216,0.001313879,0.001105363,0.004069345,0.007034675],"category_scores_gemma":[0.002219466,0.0008298659,0.001977683,0.0003547589,0.001458751,0.001341121,0.0003801731,0.003570505,0.001353898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006835994,"about_ca_system_score_gemma":0.000791455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008466658,"about_ca_topic_score_gemma":0.001144632,"domain_scores_codex":[0.9992278,0.0003459389,0.00005001303,0.000166687,0.0000613453,0.0001482535],"domain_scores_gemma":[0.9989753,0.000370831,0.000229551,0.00006137807,0.00007471168,0.0002882949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9749346,0.003632983,0.0004901561,0.0009061573,0.0008429267,0.00006290305,0.0000608476,0.0001495132,0.003024656,0.0001097712,0.000700819,0.01508463],"study_design_scores_gemma":[0.9241015,0.07296251,0.001410004,0.00006617897,0.0003712054,0.00003823496,0.00002443798,0.0001381009,0.0002370292,0.0001157405,0.0005185968,0.00001639226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796724,0.01139489,0.0006381546,0.0007246523,0.000877304,0.003381343,0.0009069819,0.0001348264,0.002269489],"genre_scores_gemma":[0.984985,0.004655759,0.001103604,0.001554422,0.00071899,0.003002877,0.0009591297,0.00002335505,0.002996872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007034675,"threshold_uncertainty_score":0.0235334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02335166505464427,"score_gpt":0.301349708916011,"score_spread":0.2779980438613668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}